TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18025650

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma agents
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study: 16334846

Group type: EXPERIMENTAL
Intervention: MR digital subtraction angiography (MR‐DSA)
Number of subjects: 12
Study: 12030959

Group type: EXPERIMENTAL
Intervention: OAC-omeprazole
Number of subjects: 150

Group type: COMPARATOR
Intervention: OAC-placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Successful eradication
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Failed eradication
Number of subjects: 150
Study: 10687264

Group type: EXPERIMENTAL
Intervention: Eradication therapy (amoxicillin at 500 mg twice a day for 14 days, metronidazole at 500 mg twice a day for 10 days, omeprazole at 20 mg twice a day for 20 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 8914911

Group type: EXPERIMENTAL
Intervention: Epinephrine 1:100,000
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Epinephrine 1:200,000
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Epinephrine 1:400,000
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Epinephrine 1:800,000
Number of subjects: 81
Study: 1991748

Group type: EXPERIMENTAL
Intervention: Total nail avulsion
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Nail edge excision
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Nail edge excision with phenolisation of the germinal matrix
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Nail edge excision and phenolisation
Number of subjects: 163
Study: 6350408

Group type: EXPERIMENTAL
Intervention: Methacholine (M)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation with cold air (HV)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cumulative M PD20
Number of subjects: 27
Study: 30070398

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy + Cognitive Behavioral Therapy (IRT + CBT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 42
Study: 26991889

Group type: EXPERIMENTAL
Intervention: Exercise augmentation of treatment as usual (part of STRIDE trial)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Cocaine use disorder
Number of subjects: 302

Group type: COMPARATOR
Intervention: Cocaine plus other stimulant use disorders
Number of subjects: 302
Study: 25077835

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens
Number of subjects: 114
Study: 22353759

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20799973

Group type: EXPERIMENTAL
Intervention: Multifaceted community-based care program including facilitated bone mineral density testing, patient education, and patient-specific recommendations for osteoporosis treatment.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Multifaceted community-based care program
Number of subjects: 201
Study: 17608331

Group type: EXPERIMENTAL
Intervention: BioFlex system (dynamic stabilization with or without PLIF)
Number of subjects: 103

Group type: COMPARATOR
Intervention: PLIF + BioFlex system (rigid fixation)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Nitinol memory loops implanted
Number of subjects: 103
Study: 16273666

Group type: EXPERIMENTAL
Intervention: Chemoradiation (50.4 Gy, 1.8 Gy per fraction plus bolus 5-fluorouracil and leucovorin) followed by surgery after 4-6 weeks
Number of subjects: 316

Group type: COMPARATOR
Intervention: Short-course irradiation (5 x 5 Gy) followed by surgery within 7 days
Number of subjects: 316
Study: 12212870

Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 50
Study: 10540368

Group type: EXPERIMENTAL
Intervention: Intravascular stent placement
Number of subjects: 17
Study: 7573781

Group type: EXPERIMENTAL
Intervention: Low dose of ethanol (0.5 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2333581

Group type: EXPERIMENTAL
Intervention: Induction treatment with vincristine, daunorubicin, prednisone, cytosine arabinoside, and 6-thioguanine; followed by consolidation treatment with VM-26, cyclophosphamide, BCNU, and L-asparaginase; CNS prophylaxis with intrathecal methotrexate.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT) in the first complete remission (CR) for patients under 45 years with HLA identical sibs.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Autologous BMT for patients without HLA-identical sibs.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy for remaining patients.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall treatment including chemotherapy and BMT.
Number of subjects: 43
Study: 444025

Group type: EXPERIMENTAL
Intervention: Brief hospitalization followed by day care
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Brief hospitalization without day care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard inpatient care
Number of subjects: 175
Study: 31993719

Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study: 30663076

Group type: EXPERIMENTAL
Intervention: Vedolizumab at week 6
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Vedolizumab concentrations at weeks 6, 14, and steady state
Number of subjects: 693
Study: 28942450

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 90
Study: 23835670

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 60
Study: 24039459

Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate (MPH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 21358384

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 19465470

Group type: EXPERIMENTAL
Intervention: Ready‐to‐use fortified spread
Number of subjects: 491

Group type: COMPARATOR
Intervention: Corn‐soy blend
Number of subjects: 491
Study: 17557044

Group type: EXPERIMENTAL
Intervention: Endoscopic therapies (endoscopic mucosal resection, ablative therapies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening and surveillance strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risk stratification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced endoscopic techniques (narrow band imaging, autofluorescence imaging, confocal laser endomicroscopy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mainstays of treatment for advanced cancers (debulking surgery, chemotherapy, radiotherapy, palliative care)
Number of subjects: 0
Study: 15148833

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 11253158

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg/day
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/day, 400 mg/day)
Number of subjects: 768
Study: 9513236

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) chemical peel at concentrations ranging from 20% to 50%; applied 48 hours before upper-eyelid blepharoplasty.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) chemical peel at 50% concentration; applied 48 hours before upper-eyelid blepharoplasty.
Number of subjects: 10
Study: 9167210

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at 30 ng/kg/min for 48 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 2037735

Group type: EXPERIMENTAL
Intervention: Physical activity participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health Promotion Model
Number of subjects: 0
Study: 6953761

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-chemotherapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anorectics
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-anorectics
Number of subjects: 62
Study: 31023004

Group type: EXPERIMENTAL
Intervention: Neuro-QoL-Stigma Scale
Number of subjects: 152
Study: 28012804

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Baseline frequent cough (FC)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cough-specific quality of life (QoL)
Number of subjects: 142
Study: 25047089

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 54
Study: 25004186

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 23071528

Group type: EXPERIMENTAL
Intervention: Sirolimus (1.3 to 1.5 mg per day for a median of 19 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 39
Study: 19413178

Group type: EXPERIMENTAL
Intervention: GROalpha levels measured at different time points (Preop, 90 min-Xoff, 24 hours after surgery) during AAA repair
Number of subjects: 17

Group type: COMPARATOR
Intervention: GROalpha levels in patients undergoing AAA repair
Number of subjects: 17
Study: 17887998

Group type: EXPERIMENTAL
Intervention: Intrasulcular incision
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Submarginal incision
Number of subjects: 184

Group type: COMPARATOR
Intervention: Papilla base incision
Number of subjects: 184
Study: 14968218

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg thrice daily for 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg thrice daily for 5 days followed by alpha-tocopherol 200 mg thrice daily for another 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diclofenac combined with alpha-tocopherol
Number of subjects: 24
Study: 11577655

Group type: EXPERIMENTAL
Intervention: Vocational services (at least one hour)
Number of subjects: 166
Study: 9196357

Group type: EXPERIMENTAL
Intervention: Standard infant formula (SFo)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Long chain polyunsaturated fatty acid (LC‐PUFA) enriched formula (LCPFo)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Erythrocyte phosphatidylcholine and phosphatidylethanolamine (subgroup n = 20)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis including phosphatidylcholine and phosphatidylethanolamine variables
Number of subjects: 81
Study: 1531822

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 4003099

Group type: EXPERIMENTAL
Intervention: 5 mg Org 3770
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 15 mg Org 3770
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 30 mg Org 3770
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 250

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study: 30606225

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative therapy (CMT) - four treatments over a 2-week period
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control - no treatment during the 2-week period
Number of subjects: 120
Study: 29861222

Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques (MRT) for 15 minutes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (subjects in supine position for 15 minutes without intervention)
Number of subjects: 22
Study: 27133877

Group type: COMPARATOR
Intervention: NTHi vaccine formulations (10 or 30μg of each antigen PD and PE-PilA)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted formulations
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: NTHi vaccine formulations
Number of subjects: 318
Study: 24867903

Group type: EXPERIMENTAL
Intervention: Massage therapy and exercise program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exercise program alone
Number of subjects: 18
Study: 22835512

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 127

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Use of systemic antihypertensives
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Mean ocular perfusion pressure
Number of subjects: 127
Study: 20600554

Group type: EXPERIMENTAL
Intervention: Nanoemulsion (cetylpyridinium chloride-containing)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine gluconate
Number of subjects: 3

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 3
Study: 17555427

Group type: EXPERIMENTAL
Intervention: Mitemcinal 10 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 15702239

Group type: EXPERIMENTAL
Intervention: Shoyu polysaccharides (SPS) 600 mg daily
Number of subjects: 51
Study: 11833398

Group type: EXPERIMENTAL
Intervention: Kinesthetic training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Handwriting practice
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study: 10513175

Group type: EXPERIMENTAL
Intervention: Hypothermic group (H, n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normothermic group (N, n = 23)
Number of subjects: 47
Study: 9395621

Group type: EXPERIMENTAL
Intervention: HP-200 (7.5 g sachet mixed with water, orally)
Number of subjects: 60
Study: 1715501

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (4 IU/m2 per day) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 20
Study: 6857511

Group type: COMPARATOR
Intervention: Ringer's lactate solution (RL, 130 mEq sodium/L, 274 mOsm/L)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hypertonic balanced salt solution (HSL, 250 mEq sodium/L, 514 mOsm/L)
Number of subjects: 58
Study: 31315238

Group type: EXPERIMENTAL
Intervention: Total dairy product consumption (highest vs lowest quartile)
Number of subjects: 49472

Group type: EXPERIMENTAL
Intervention: Regular-fat dairy product intake (highest vs lowest quartile)
Number of subjects: 49472

Group type: EXPERIMENTAL
Intervention: 2%-fat milk intake (higher than median vs no intake)
Number of subjects: 49472
Study: 29769829

Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 25669236

Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy (SCBT)
Number of subjects: 132
Study: 24121692

Group type: EXPERIMENTAL
Intervention: Water-based gel applied during speculum examination
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Dry speculum (control group)
Number of subjects: 1580
Study: 22502741

Group type: EXPERIMENTAL
Intervention: Visualization of an abstract verbal stimulus
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Verbalization of the sentence
Number of subjects: 180

Group type: COMPARATOR
Intervention: Concrete sentence condition
Number of subjects: 180

Group type: COMPARATOR
Intervention: Abstract sentence condition
Number of subjects: 180
Study: 20368815

Group type: EXPERIMENTAL
Intervention: SP plus 3 days of artesunate (SP-AS3)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: 3 days of amodiaquine-artesunate (AQ3-AS3)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: 3 days of short-acting chlorproguanil-dapsone (CD3)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: SP-AS3
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: AQ3-AS3
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: CD3
Number of subjects: 1365
Study: 17397731

Group type: EXPERIMENTAL
Intervention: AcrySof IQ SN60WF IOL
Number of subjects: 120

Group type: COMPARATOR
Intervention: AcrySof SA60AT IOL
Number of subjects: 120

Group type: COMPARATOR
Intervention: AcrySof Natural SN60AT IOL
Number of subjects: 120
Study: 15878927

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 microg followed by 400 microg every 3 hours)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg followed by 400 microg every 3 hours)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 76
Study: 12208402

Group type: EXPERIMENTAL
Intervention: 1 long stent (GFX II stents or S670 of 24, 30, or 40 mm lengths; n = 62)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 2 short stents (GFX II or S670 stents, n = 62)
Number of subjects: 124
Study: 9620907

Group type: EXPERIMENTAL
Intervention: Nutritional therapy alone (n = 71)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Nutritional therapy in combination with anabolic steroid treatment (n = 67)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Weight change as a time‐dependent covariate
Number of subjects: 603
Study: 8077349

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2921681

Group type: EXPERIMENTAL
Intervention: Humidified oxygen
Number of subjects: 28

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 28
Study: 31628954

Group type: EXPERIMENTAL
Intervention: Underwater resection (UR)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Conventional resection (CR)
Number of subjects: 255
Study: 31182491

Group type: EXPERIMENTAL
Intervention: Med‐EatPlan + EVOO
Number of subjects: 3230

Group type: EXPERIMENTAL
Intervention: Med‐EatPlan + nuts
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Control eating plan
Number of subjects: 3230
Study: 27826654

Group type: EXPERIMENTAL
Intervention: HI (high-intensity exercise starting at 105% of the incremental peak power)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: I-BFR30 (intermittent BFR at 30% P peak)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C-BFR30 (continuous BFR at 30% P peak)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON30 (control exercise without BFR at 30% P peak)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: I-BFR0 (intermittent BFR during unloaded exercise)
Number of subjects: 12
Study: 23490255

Group type: EXPERIMENTAL
Intervention: Multivitamins (folic acid 0.8 mg, vitamin B6 10 mg, and vitamin B12 500 μg)
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8000
Study: 22333695

Group type: EXPERIMENTAL
Intervention: Thimerosal-free trivalent inactivated influenza vaccine
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Control vaccine (US-licensed influenza vaccine)
Number of subjects: 2116
Study: 20374974

Group type: EXPERIMENTAL
Intervention: ADAPT-232 (270mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18535254

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Medical control
Number of subjects: 1078
Study: 16075286

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11813149

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brachytherapy alone
Number of subjects: 0
Study: 10070201

Group type: EXPERIMENTAL
Intervention: 4-kHz tones with masker levels ranging from 5 to 35 dB/Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5-kHz tones with masker levels ranging from 5 to 35 dB/Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-msec stimuli of 0.5-kHz tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100-msec stimuli of 0.5-kHz tones
Number of subjects: 0
Study: 9420639

Group type: EXPERIMENTAL
Intervention: 100 mg coenzyme Q10 (CoQ10)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 2261301

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: metrizoate
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Delayed excretion greater than 10 min
Number of subjects: 43

Group type: COMPARATOR
Intervention: No delayed excretion
Number of subjects: 43
Study: 7396058

Group type: EXPERIMENTAL
Intervention: Amoxicillin (375 mg, 3 times a day for 5 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (6‐aminopenicillanic acid)
Number of subjects: 15
Study: 30901380

Group type: COMPARATOR
Intervention: PF‐00547659 (anti-MAdCAM-1 monoclonal antibody)
Number of subjects: 357
Study: 29032705

Group type: EXPERIMENTAL
Intervention: MTA app
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control patient portal (PP) app
Number of subjects: 72
Study: 27240673

Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 1148
Study: 24699015

Group type: EXPERIMENTAL
Intervention: Speed stress condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accuracy stress condition
Number of subjects: 0